Adverse event rates following primary PCI for STEMI at US and non-US hospitals: Three-year analysis from the HORIZONS-AMI trial

EuroIntervention

Volumn 8, Issue 10, 2013, Pages 1134-1142

  Tobbia, Patrick ^a   Brodie, Bruce R ^a   Witzenbichler, Bernhard ^b   Metzger, Chris ^c   Guagliumi, Giulio ^d   Yu, Jennifer ^e   Kellett, Mirle A ^f   Stuckey, Thomas ^a   Fahy, Martin ^g   Mehran, Roxana ^e,g   Stone, Gregg W ^g,h  

^a MOSES H CONE MEMORIAL HOSPITAL   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Wellmont CVA Heart Institute   (United States)

^d OSPEDALI RIUNITI   (Italy)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f MAINE MEDICAL CENTER   (United States)

^g CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^h NewYork Presbyterian Hospital   (United States)

Author keywords

Bivalirudin; Geographical variations; Primary PCI; STEMI

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL;

ADULT; AGED; ARTICLE; BARE METAL STENT; BLEEDING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; HEART DISEASE; HEART REINFARCTION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNITED STATES;

EID: 84878288433     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV8I10A176     Document Type: Article

References (12)

1. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271-306.
2. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909-45.
3. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20. (Pubitemid 36050955)
4. Van de Werf F, Topol EJ, Lee KL, Woodlief LH, Granger CB, Armstrong PW, Barbash GI, Hampton JR, Guerci A, Simes RJ. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. JAMA. 1995;273:1586-91.
5. Giugliano RP, Llevadot J, Wilcox RG, Gurfinkel EP, McCabe CH, Charlesworth A, Thompson SL, Antman EM, Braunwald E. Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-segment elevation myocardial infarction treated with fibrinolysis. Eur Heart J. 2001;22: 1702-15. (Pubitemid 32896370)
6. Barbash GI, Modan M, Goldbourt U, White HD, Van de Werf F. Comparative case fatality analysis of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial: variation by country beyond predictive profile. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol. 1993;21:281-6. (Pubitemid 23047906)
7. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008; 358:2218-30. (Pubitemid 351724451)
8. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011;377:2193-204.
9. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51. (Pubitemid 46685903)
10. Raisch DW, Troutman WG, Sather MR, Fudala PJ. Variability in the assessment of adverse events in a multicenter clinical trial. Clin Ther. 2001;23:2011-20. (Pubitemid 34073192)
11. Kociol RD, Lopes RD, Clare R, Thomas L, Mehta RH, Kaul P, Pieper KS, Hochman JS, Weaver WD, Armstrong PW, Granger CB, Patel MR. International variation in and factors associated with hospital readmission after myocardial infarction. JAMA. 2012;307:66-74.
12. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L; PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124:544-54.